View Larger
Beverly S. Mitchell, M.D.
Academic Appointments
- Professor, Medicine - Oncology
- Member, Stanford Cancer Institute
- Professor, Medicine - Hematology
- Professor (By courtesy), Chemical and Systems Biology
Key Documents
Contact Information
-
Clinical Offices
Stanford Clinical Cancer Center 875 Blake Wilbur Drive Stanford, CA 94305 Tel Work (650) 725-9621 Fax (650) 736-0607
- Academic Offices
Personal Information Email Tel (650) 736-7716Alternate Contact Natalie Huen Administrative Assistant Email Tel Work 650.736.7716Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Hematology
- Cancer> Hematology> Hematologic Malignancies
- Cancer> Lymphoma
- Hematology
Administrative Appointments
- Director, Stanford Cancer Institute (2008 - present)
- Deputy Director, Stanford Cancer Center (2005 - 2008)
Honors and Awards
- Walter Hewlitt Physician Scientist Award, Stanford Department of Medicine (2012)
- Mentorship Award, American Society of Hematology (2012)
- President, American Society of Hematology (2001)
- Member, American Society for Clinical Investigation (to present)
- Member, Association of American Professors (1991)
- National Academy of Sciences, Institute of Medicine (Inducted 2001)
Professional Education
| Medical Education: | Harvard Medical School MA (1969) |
| Board Certification: | Hematology, American Board of Internal Medicine (1978) |
| Fellowship: | University Hospital Zurich, Switzerland (1973) |
| Fellowship: | University of Michigan Hospital MI (1977) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (1973) |
| Residency: | University of Washington WA (1973) |
Graduate & Fellowship Program Affiliations
Scientific Focus
Current Research Interests
Beverly S. Mitchell, MD, is the Director of the Stanford Cancer Institute and is the George E. Becker Professor of Medicine at Stanford University. Before joining the Stanford faculty, Dr. Mitchell lead the Molecular Therapeutics Program at UNC Chapel Hill's Lineberger Comprehensive Cancer Center, where she also served as Associate Director for Translational Research and Chief of the Division of Hematology/Oncology.
She has authored over 130 peer-reviewed articles. She served as President of the American Society of Hematology (ASH) and was Chair of the Medical and Scientific Affairs Committee and Vice Chair for Medical and Scientific Affairs of the Leukemia and Lymphoma Society of America.
Dr. Mitchell's current research relates to the development of new therapies for hematologic malignancies. She is interested in preclinical proof of principle studies on mechanisms inducing cell death and on metabolic targets involving nucleic acid biosynthesis in malignant cells. Recent studies have focused on the role of nucleolar proteins in cellular stress responses, including that induced by reactive oxygen species. She is also interested in the regulation of ribosomal RNA synthesis in hematopoietic stem and progenitor cells and in the role of dysregulated synthesis in bone marrow failure syndromes. in addition, her laboratory is involved in the translation of these studies into scientifically designed clinical trials.
Publications
- Effect of nucleophosmin1 haploinsufficiency on hematopoietic stem cells. Leukemia. 2012; (4): 853-5
- Reduced rRNA expression and increased rDNA promoter methylation in CD34+ cells of patients with myelodysplastic syndromes. Blood. 2012; (24): 4812-8
- Cyclopentenyl cytosine induces senescence in breast cancer cells through the nucleolar stress response and activation of p53. Mol Pharmacol. 2011; (1): 40-8
- Reactive oxygen species regulate nucleostemin oligomerization and protein degradation. J Biol Chem. 2011; (13): 11035-46
- Depletion of guanine nucleotides leads to the Mdm2-dependent proteasomal degradation of nucleostemin. Cancer Res. 2009; (7): 3004-12
- Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H. Leuk Res. 2008; (8): 1268-78
Help